Inhibikase Therapeutics Inc (IKT)
R&D Expense Growth
23.57%
Quarterly · Period ending:
IKT R&D Expense Growth
Latest reported23.57%period ending
Latest reported23.57%period ending
IKT Quarterly R&D Growth (QoQ) (0.00% → 23.57%)
Latest values, visible window
High-resolution chart · PNG
IKT r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 23.5656% | |
| 70.4563% | |
| -16.8738% | |
| 45.1289% | |
| -49.8652% | |
| 46.2861% | |
| 71.5326% | |
| 36.2193% | |
| 11.7964% | |
| -8.3817% | |
| -6.9002% | |
| -28.8852% | |
| 58.9176% | |
| -6.5497% | |
| 2.4317% | |
| -0.0178% | |
| -1.1537% | |
| -11.01% | |
| 7.4719% | |
| 32.4089% | |
| -2.0325% | |
| 971.5683% | |
| 88.2275% | |
| -54.1868% | |
| -7.0427% | |
| 5.6731% | |
| 5.0779% | |
| -46.2146% | |
| -69.53% | |
| 6.4782% | |
| 0% | |
| -2.4712% | |
| 0% | |
| 0% |